News

Read about the progress of individual NINDS PDBP projects and learn about presentations and workshops that are relevant to the PDBP.

Recent Publications

Pallidal beta bursts in Parkinson's disease and dystonia.

  • Lofredi R
  • Neumann WJ
  • Brücke C
  • Huebl J
  • Krauss JK
  • Schneider GH
  • Kühn AA
α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.

  • van Steenoven I
  • Majbour NK
  • Vaikath NN
  • Berendse HW
  • van der Flier WM
  • van de Berg WDJ
  • Teunissen CE
  • Lemstra AW
  • El-Agnaf OMA
Progressively Disrupted Somatodendritic Morphology in Dopamine Neurons in a Mouse Parkinson's Model.

  • Lynch WB
  • Tschumi CW
  • Sharpe AL
  • Branch SY
  • Chen C
  • Ge G
  • Li S
  • Beckstead MJ
Bioactivity of selected materials for coffee substitute.

  • Zawirska-Wojtasiak R
  • Piechowska P
  • Wojtowicz E
  • Przygoński K
  • Mildner-Szkudlarz S

Press releases, workshop summaries, and editorials

Accelerating Research for Parkinson’s Disease

The Accelerating Medicines Partnership Parkinson's disease (AMP PD) program, launched on Jan 30, 2018, is the most ambitious initiative so far to find a cure for Parkinson's disease. Formed by the US National Institutes of Health (NIH), the US Food and Drug Administration (FDA), five biopharmaceutical and life science companies, and the Michael J. Fox Foundation, this partnership is focused on discovering novel therapeutic targets and on developing biomarkers to help validate existing therapeutic targets for Parkinson's disease.

AMP PD

 

NIH launches partnership to improve success of clinical trials for patients with Parkinson’s disease

“Advancing treatments for Parkinson’s disease is hampered by insufficient understanding of biological networks; drugs aimed at seemingly promising therapeutic targets fail in clinical trials,” said NIH Director Francis S. Collins, M.D., Ph.D. “By combining our expertise and resources, AMP PD partners hope to increase our collective odds of success in accelerating the development of effective treatments for a million Americans who suffer from this debilitating disease.”